It is a long-acting amylin analog, a completely different mechanism from the GLP-1 receptor agonists that dominate the conversation right now
[7] Two trials in the phase 3 TRIUMPH program reached primary completion in April 2026: TRIUMPH-1, a master protocol in adults with obesity or overweight, and TRIUMPH-3, in participants with severe obesity and established cardiovascular disease
Reliable medications Carefully selected ingredients tailored to support your weight management journey and your lifestyle
It is not a drug, supplement, cosmetic, or food, and is not for human or veterinary use, injection, or ingestion
Consequently, food becomes less compelling rather than forbidden